ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review
Medical Oncology · 2026
DOI: 10.1007/s12032-026-03378-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Medical Oncology, 2026. Verfasst von Lucas Oliveira Laurindo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Cytogenomic Laboratory, Federal University of Ceara (UFC), Fortaleza, Ceara, Brazil. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, Leukemia, Myeloid, Acute, Mutation, Myelodysplastic Syndromes. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade Federal Do Ceará.
Abstract (Originalsprache)
Ataxia Telangiectasia Mutated ( ATM ), a central kinase in the DNA damage response, is recurrently altered across these disorders, including myelodysplastic neoplasms (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms (MPN), yet its clinical significance remains underrecognized. We conducted a PROSPERO-registered systematic review (CRD420251142673) to evaluate the prognostic and biological impact of ATM alterations in MDS, AML, and MPN. Ten studies met inclusion criteria. In MDS, ATM alterations showed consistent downregulation, hypermethylation, and a predominance of oncogenic missense mutations, with methylation significantly enriched in cases progressing to AML. In AML, reduced ATM gene expression, often driven by miR-100 or miR-181a, was associated with increased blast proliferation, while the ATM genetic variant rs3092856 correlated with chemoresistance and inferior survival. Evidence in MPN/CML, although limited, suggests that ATM polymorphisms, such as rs228593, rs3092856 (C4138T), −5144A>T (rs228589), c.5753G>C, c.346A>G, c.4060C>A, and the germline variant L2307F, contribute to disease susceptibility and adverse prognostic stratification. Collectively, current evidence supports ATM alterations as clinically relevant biomarkers in myeloid malignancies, although their functional role in disease pathogenesis remains incompletely understood.. Rather than establishing ATM merely as a prognostic marker, future efforts should prioritize the characterization of ATM -related therapeutic vulnerabilities and integrate ATM status into treatment-oriented molecular panels to guide precision-based interventions in myeloid diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Cytogenomic Laboratory, Federal University of Ceara (UFC), Fortaleza, Ceara, Brazil.
- Drug Research and Development Center (NPDM), Federal University of Ceara, Fortaleza, Ceara, Brazil.
- Cancer Cytogenomic Laboratory, Federal University of Ceara (UFC), Fortaleza, Ceara, Brazil. luri.sasahara@gmail.com.
- Drug Research and Development Center (NPDM), Federal University of Ceara, Fortaleza, Ceara, Brazil. luri.sasahara@gmail.com.
- Department of Clinical and Experimental Oncology (DOCE), Federal University of São Paulo, São Paulo, Brazil.
- Cancer Cytogenomic Laboratory, Federal University of Ceara (UFC), Fortaleza, Ceara, Brazil. pinheirorfeitosa@gmail.com.
Förderung
- Universidade Federal Do Ceará
Zitieren
APA
Laurindo, L. O., Parente, M. L. B., Sasahara, G. L., Goes, J. V. C., Sampaio, L. R., Pinheiro, Y. V., & Pinheiro, R. F. (2026). ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review. Medical Oncology. https://doi.org/10.1007/s12032-026-03378-4
Vancouver
Laurindo LO, Parente MLB, Sasahara GL, Goes JVC, Sampaio LR, Pinheiro YV, et al. ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review. Medical Oncology. 2026. doi:10.1007/s12032-026-03378-4
BibTeX
@article{Laurindo2026,
author = {Laurindo, Lucas Oliveira and Parente, Marjori Lima Boblitz and Sasahara, Greyce Luri and Goes, João Vitor Caetano and Sampaio, Letícia Rodrigues and Pinheiro, Yuri Vasconcelos and Pinheiro, Ronald Feitosa},
title = {ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review},
journal = {Medical Oncology},
year = {2026},
doi = {10.1007/s12032-026-03378-4}
}
EUVIMED